Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Contemporary Implications of U.S. Preventive Services Task Force and Risk-Based Guidelines for Lung Cancer Screening Eligibility in the United States.

Landy R, Cheung LC, Berg CD, Chaturvedi AK, Robbins HA, Katki HA.

Ann Intern Med. 2019 Jun 4. doi: 10.7326/M18-3617. [Epub ahead of print] No abstract available.

PMID:
31158854
2.

Insights for Management of Ground-Glass Opacities From the National Lung Screening Trial.

Robbins HA, Katki HA, Cheung LC, Landy R, Berg CD.

J Thorac Oncol. 2019 May 22. pii: S1556-0864(19)30378-8. doi: 10.1016/j.jtho.2019.05.012. [Epub ahead of print]

PMID:
31125735
3.

Benefits and harms in the National Lung Screening Trial: expected outcomes with a modern management protocol.

Robbins HA, Callister M, Sasieni P, Quaife SL, Cheung LC, Brennan P, Katki HA, Berg CD, Baldwin D, Johansson M.

Lancet Respir Med. 2019 Aug;7(8):655-656. doi: 10.1016/S2213-2600(19)30136-5. Epub 2019 May 7. No abstract available. Erratum in: Lancet Respir Med. 2019 Jul;7(7):e22.

PMID:
31076382
4.

Identification of candidates for longer lung cancer screening intervals following a negative low-dose computed tomography result.

Robbins HA, Berg CD, Cheung LC, Chaturvedi AK, Katki HA.

J Natl Cancer Inst. 2019 Apr 12. pii: djz041. doi: 10.1093/jnci/djz041. [Epub ahead of print]

PMID:
30976808
5.

Prioritized concordance index for hierarchical survival outcomes.

Cheung LC, Pan Q, Hyun N, Katki HA.

Stat Med. 2019 Jul 10;38(15):2868-2882. doi: 10.1002/sim.8157. Epub 2019 Apr 7.

PMID:
30957257
6.

Targeting the bone marrow microenvironment: a novel therapeutic strategy for pre-B acute lymphoblastic leukemia.

Kotecha RS, Cheung LC.

Oncotarget. 2019 Mar 5;10(19):1756-1757. doi: 10.18632/oncotarget.26720. eCollection 2019 Mar 5. No abstract available.

7.

Absolute risks of cervical precancer among women who fulfill exiting guidelines based on HPV and cytology cotesting.

Landy R, Schiffman M, Sasieni PD, Cheung LC, Katki HA, Rydzak G, Wentzensen N, Poitras NE, Lorey T, Kinney WK, Castle PE.

Int J Cancer. 2019 Mar 12. doi: 10.1002/ijc.32268. [Epub ahead of print]

PMID:
30861114
8.

Romidepsin enhances the efficacy of cytarabine in vivo, revealing histone deacetylase inhibition as a promising therapeutic strategy for KMT2A-rearranged infant acute lymphoblastic leukemia.

Cheung LC, Cruickshank MN, Hughes AM, Singh S, Chua GA, Ford J, Ferrari E, Oommen J, Malinge S, Lock RB, Kees UR, Kotecha RS.

Haematologica. 2019 Jul;104(7):e300-e303. doi: 10.3324/haematol.2018.192906. Epub 2019 Jan 24. No abstract available.

9.

Role of Screening History in Clinical Meaning and Optimal Management of Positive Cervical Screening Results.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Poitras NE, Lorey TS, Katki HA, Wentzensen N, Schiffman M.

J Natl Cancer Inst. 2018 Dec 21. doi: 10.1093/jnci/djy192. [Epub ahead of print]

PMID:
30576462
10.

Five-year prospective evaluation of cytology, HPV testing, and biomarkers for detection of anal precancer in HIV+ MSM.

Clarke MA, Cheung LC, Lorey T, Hare B, Landy R, Tokugawa D, Gage JC, Darragh TM, Castle PE, Wentzensen N.

Clin Infect Dis. 2018 Nov 12. doi: 10.1093/cid/ciy970. [Epub ahead of print]

PMID:
30418518
11.

Is bridge to surgery stenting a safe alternative to emergency surgery in malignant colonic obstruction: a meta-analysis of randomized control trials.

Foo CC, Poon SHT, Chiu RHY, Lam WY, Cheung LC, Law WL.

Surg Endosc. 2019 Jan;33(1):293-302. doi: 10.1007/s00464-018-6487-3. Epub 2018 Oct 19.

PMID:
30341649
12.

Five-Year Risk of Cervical Precancer Following p16/Ki-67 Dual-Stain Triage of HPV-Positive Women.

Clarke MA, Cheung LC, Castle PE, Schiffman M, Tokugawa D, Poitras N, Lorey T, Kinney W, Wentzensen N.

JAMA Oncol. 2019 Feb 1;5(2):181-186. doi: 10.1001/jamaoncol.2018.4270.

PMID:
30325982
13.

A novel, palatable paediatric oral formulation of midazolam: pharmacokinetics, tolerability, efficacy and safety.

Salman S, Tang EKY, Cheung LC, Nguyen MN, Sommerfield D, Slevin L, Lim LY, von Ungern Sternberg BS.

Anaesthesia. 2018 Dec;73(12):1469-1477. doi: 10.1111/anae.14318. Epub 2018 Jul 9.

PMID:
29984832
14.

Implications of Nine Risk Prediction Models for Selecting Ever-Smokers for Computed Tomography Lung Cancer Screening.

Katki HA, Kovalchik SA, Petito LC, Cheung LC, Jacobs E, Jemal A, Berg CD, Chaturvedi AK.

Ann Intern Med. 2018 Jul 3;169(1):10-19. doi: 10.7326/M17-2701. Epub 2018 May 15.

15.

New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.

Cheung LC, Tickner J, Hughes AM, Skut P, Howlett M, Foley B, Oommen J, Wells JE, He B, Singh S, Chua GA, Ford J, Mullighan CG, Kotecha RS, Kees UR.

Leukemia. 2018 Nov;32(11):2326-2338. doi: 10.1038/s41375-018-0144-7. Epub 2018 May 8.

16.

Low Risk of Cervical Cancer/Precancer Among Most Women Under Surveillance Postcolposcopy.

Demarco M, Cheung LC, Kinney WK, Wentzensen N, Lorey TS, Fetterman B, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2018 Apr;22(2):97-103. doi: 10.1097/LGT.0000000000000382.

17.

Clinical Outcomes after Conservative Management of Cervical Intraepithelial Neoplasia Grade 2 (CIN2) in Women Ages 21-39 Years.

Silver MI, Gage JC, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Katki HA, Locke A, Kinney WK, Castle PE.

Cancer Prev Res (Phila). 2018 Mar;11(3):165-170. doi: 10.1158/1940-6207.CAPR-17-0293. Epub 2018 Feb 5.

18.

Epidemiologic Evidence That Excess Body Weight Increases Risk of Cervical Cancer by Decreased Detection of Precancer.

Clarke MA, Fetterman B, Cheung LC, Wentzensen N, Gage JC, Katki HA, Befano B, Demarco M, Schussler J, Kinney WK, Raine-Bennett TR, Lorey TS, Poitras NE, Castle PE, Schiffman M.

J Clin Oncol. 2018 Apr 20;36(12):1184-1191. doi: 10.1200/JCO.2017.75.3442. Epub 2018 Jan 22.

19.

Preventing Lung Cancer Mortality by Computed Tomography Screening: The Effect of Risk-Based Versus U.S. Preventive Services Task Force Eligibility Criteria, 2005-2015.

Cheung LC, Katki HA, Chaturvedi AK, Jemal A, Berg CD.

Ann Intern Med. 2018 Feb 6;168(3):229-232. doi: 10.7326/M17-2067. Epub 2018 Jan 2. No abstract available.

PMID:
29297008
20.

Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting.

Rendle KA, Schiffman M, Cheung LC, Kinney WK, Fetterman B, Poitras NE, Lorey T, Castle PE.

Prev Med. 2018 Apr;109:44-50. doi: 10.1016/j.ypmed.2017.12.023. Epub 2017 Dec 27.

PMID:
29288782
21.

Challenges in risk estimation using routinely collected clinical data: The example of estimating cervical cancer risks from electronic health-records.

Landy R, Cheung LC, Schiffman M, Gage JC, Hyun N, Wentzensen N, Kinney WK, Castle PE, Fetterman B, Poitras NE, Lorey T, Sasieni PD, Katki HA.

Prev Med. 2018 Jun;111:429-435. doi: 10.1016/j.ypmed.2017.12.004. Epub 2017 Dec 6.

22.

Effect of Several Negative Rounds of Human Papillomavirus and Cytology Co-testing on Safety Against Cervical Cancer: An Observational Cohort Study.

Castle PE, Kinney WK, Xue X, Cheung LC, Gage JC, Zhao FH, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Katki HA, Schiffman M.

Ann Intern Med. 2018 Jan 2;168(1):20-29. doi: 10.7326/M17-1609. Epub 2017 Nov 28.

PMID:
29181509
23.

Relative Performance of HPV and Cytology Components of Cotesting in Cervical Screening.

Schiffman M, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Castle PE.

J Natl Cancer Inst. 2018 May 1;110(5):501-508. doi: 10.1093/jnci/djx225.

24.

Taste evaluation of a novel midazolam tablet for pediatric patients: In vitro drug dissolution, in vivo animal taste aversion and clinical taste perception profiles.

Cheung LC, Nguyen M, Tang E, von Ungern Sternberg BS, Salman S, Tuleu C, Mohamed Ahmed AHA, Soto J, Lim LY.

Int J Pharm. 2018 Jan 15;535(1-2):194-200. doi: 10.1016/j.ijpharm.2017.10.060. Epub 2017 Nov 11.

PMID:
29104056
25.

Risks of CIN 2+, CIN 3+, and Cancer by Cytology and Human Papillomavirus Status: The Foundation of Risk-Based Cervical Screening Guidelines.

Demarco M, Lorey TS, Fetterman B, Cheung LC, Guido RS, Wentzensen N, Kinney WK, Poitras NE, Befano B, Castle PE, Schiffman M.

J Low Genit Tract Dis. 2017 Oct;21(4):261-267. doi: 10.1097/LGT.0000000000000343.

26.

Potential Impact of Including Time to First Cigarette in Risk Models for Selecting Ever-Smokers for Lung Cancer Screening.

Gu F, Cheung LC, Freedman ND, Katki HA, Caporaso NE.

J Thorac Oncol. 2017 Nov;12(11):1646-1653. doi: 10.1016/j.jtho.2017.08.001. Epub 2017 Aug 14.

27.

Mixture models for undiagnosed prevalent disease and interval-censored incident disease: applications to a cohort assembled from electronic health records.

Cheung LC, Pan Q, Hyun N, Schiffman M, Fetterman B, Castle PE, Lorey T, Katki HA.

Stat Med. 2017 Sep 30;36(22):3583-3595. doi: 10.1002/sim.7380. Epub 2017 Jun 28.

28.

Why does cervical cancer occur in a state-of-the-art screening program?

Castle PE, Kinney WK, Cheung LC, Gage JC, Fetterman B, Poitras NE, Lorey TS, Wentzensen N, Befano B, Schussler J, Katki HA, Schiffman M.

Gynecol Oncol. 2017 Sep;146(3):546-553. doi: 10.1016/j.ygyno.2017.06.003. Epub 2017 Jun 10.

29.

FLEXIBLE RISK PREDICTION MODELS FOR LEFT OR INTERVAL-CENSORED DATA FROM ELECTRONIC HEALTH RECORDS.

Hyun N, Cheung LC, Pan Q, Schiffman M, Katki HA.

Ann Appl Stat. 2017 Jun;11(2):1063-1084. doi: 10.1214/17-AOAS1036. Epub 2017 Jul 20.

30.

A cohort study of cervical screening using partial HPV typing and cytology triage.

Schiffman M, Hyun N, Raine-Bennett TR, Katki H, Fetterman B, Gage JC, Cheung LC, Befano B, Poitras N, Lorey T, Castle PE, Wentzensen N.

Int J Cancer. 2016 Dec 1;139(11):2606-15. doi: 10.1002/ijc.30375. Epub 2016 Aug 26.

31.

Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.

Cruickshank MN, Ford J, Cheung LC, Heng J, Singh S, Wells J, Failes TW, Arndt GM, Smithers N, Prinjha RK, Anderson D, Carter KW, Gout AM, Lassmann T, O'Reilly J, Cole CH, Kotecha RS, Kees UR.

Leukemia. 2017 Jan;31(1):40-50. doi: 10.1038/leu.2016.165. Epub 2016 Jun 13.

32.

Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.

Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK.

JAMA. 2016 Jun 7;315(21):2300-11. doi: 10.1001/jama.2016.6255.

33.

High expression of connective tissue growth factor accelerates dissemination of leukaemia.

Wells JE, Howlett M, Halse HM, Heng J, Ford J, Cheung LC, Samuels AL, Crook M, Charles AK, Cole CH, Kees UR.

Oncogene. 2016 Sep 1;35(35):4591-600. doi: 10.1038/onc.2015.525. Epub 2016 Jan 25.

PMID:
26804166
34.

A joint model of persistent human papillomavirus infection and cervical cancer risk: Implications for cervical cancer screening.

Katki HA, Cheung LC, Fetterman B, Castle PE, Sundaram R.

J R Stat Soc Ser A Stat Soc. 2015 Oct 1;178(4):903-923. Epub 2015 Mar 17.

35.

Risk Stratification Using Human Papillomavirus Testing among Women with Equivocally Abnormal Cytology: Results from a State-Wide Surveillance Program.

Gage JC, Hunt WC, Schiffman M, Katki HA, Cheung LC, Cuzick J, Myers O, Castle PE, Wheeler CM; New Mexico HPV Pap Registry Steering Committee.

Cancer Epidemiol Biomarkers Prev. 2016 Jan;25(1):36-42. doi: 10.1158/1055-9965.EPI-15-0669. Epub 2015 Oct 30.

36.

The role of CCN family genes in haematological malignancies.

Wells JE, Howlett M, Cheung LC, Kees UR.

J Cell Commun Signal. 2015 Sep;9(3):267-78. doi: 10.1007/s12079-015-0296-4. Epub 2015 May 31.

37.

Pain management programme for Chinese patients: a 10-year outcome review.

Chu MC, Law RK, Cheung LC, Ma ML, Tse EY, Wong TC, Chen PP.

Hong Kong Med J. 2015 Aug;21(4):304-9. doi: 10.12809/hkmj144350. Epub 2015 Apr 9.

38.

Response.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Dec 26;107(1):390. doi: 10.1093/jnci/dju390. Print 2015 Jan. No abstract available.

39.

Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection.

Gage JC, Katki HA, Schiffman M, Fetterman B, Poitras NE, Lorey T, Cheung LC, Castle PE, Kinney WK.

Int J Cancer. 2015 Apr 1;136(7):1665-71. doi: 10.1002/ijc.29143. Epub 2014 Sep 2.

40.

Fermentative polyhydroxybutyrate production from a novel feedstock derived from bakery waste.

Pleissner D, Lam WC, Han W, Lau KY, Cheung LC, Lee MW, Lei HM, Lo KY, Ng WY, Sun Z, Melikoglu M, Lin CS.

Biomed Res Int. 2014;2014:819474. doi: 10.1155/2014/819474. Epub 2014 Jul 20.

41.

The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.

Gage JC, Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Behrens C, Sharma A, Zhao FH, Cuzick J, Yang ZH, Kinney WK.

Cancer Cytopathol. 2014 Nov;122(11):842-50. doi: 10.1002/cncy.21463. Epub 2014 Jul 9.

42.

Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test.

Gage JC, Schiffman M, Katki HA, Castle PE, Fetterman B, Wentzensen N, Poitras NE, Lorey T, Cheung LC, Kinney WK.

J Natl Cancer Inst. 2014 Jul 18;106(8). pii: dju153. doi: 10.1093/jnci/dju153. Print 2014 Aug.

43.

Connective tissue growth factor is expressed in bone marrow stromal cells and promotes interleukin-7-dependent B lymphopoiesis.

Cheung LC, Strickland DH, Howlett M, Ford J, Charles AK, Lyons KM, Brigstock DR, Goldschmeding R, Cole CH, Alexander WS, Kees UR.

Haematologica. 2014 Jul;99(7):1149-56. doi: 10.3324/haematol.2013.102327. Epub 2014 Apr 11.

44.

Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S78-84. doi: 10.1097/LGT.0b013e31828543c5.

45.

Follow-up testing after colposcopy: five-year risk of CIN 2+ after a colposcopic diagnosis of CIN 1 or less.

Katki HA, Gage JC, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S69-77. doi: 10.1097/LGT.0b013e31828543b1.

46.

Five-year risk of CIN 3+ to guide the management of women aged 21 to 24 years.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S64-8. doi: 10.1097/LGT.0b013e3182854399.

47.

Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S56-63. doi: 10.1097/LGT.0b013e318285437b.

48.

Five-year risks of CIN 3+ and cervical cancer among women with HPV-positive and HPV-negative high-grade Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S50-5. doi: 10.1097/LGT.0b013e3182854282.

49.

Five-year risks of CIN 2+ and CIN 3+ among women with HPV-positive and HPV-negative LSIL Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S43-9. doi: 10.1097/LGT.0b013e3182854269.

50.

Five-year risks of CIN 3+ and cervical cancer among women with HPV testing of ASC-US Pap results.

Katki HA, Schiffman M, Castle PE, Fetterman B, Poitras NE, Lorey T, Cheung LC, Raine-Bennett T, Gage JC, Kinney WK.

J Low Genit Tract Dis. 2013 Apr;17(5 Suppl 1):S36-42. doi: 10.1097/LGT.0b013e3182854253.

Supplemental Content

Loading ...
Support Center